Immuron Receives FDA Approval for Travelan IND Application
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2022
0mins
Source: globenewswire
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMRN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMRN
About IMRN
Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), and IMM-529.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy
- Strategic Partnership: Immuron has engaged Pullan Consulting to leverage their expertise in biotechnology to advance the clinical development and commercialization of IMM-529, thereby enhancing the product's market value and accelerating its path to market.
- FDA Approval Progress: The clinical development of IMM-529 has received IND approval from the U.S. FDA specifically for the prevention and treatment of Clostridioides difficile infection (CDI), establishing a solid foundation for market entry and potentially addressing a market need affecting over 400,000 individuals annually.
- Clinical Trial Design: The Phase 2 clinical trial for IMM-529 will enroll up to 60 patients using a randomized, double-blind, placebo-controlled design, primarily assessing safety and tolerability, which aligns with the fast-track Clinical Trial Notification (CTN) scheme and will provide critical data for future market promotion.
- Market Potential Assessment: According to Lumanity's assessment, if IMM-529 proves effective, it could generate annual revenues of $400 million, and its early positioning in treatment algorithms will provide a competitive advantage in a crowded market, further driving Immuron's business growth.
See More
Immuron Reports 16% Sales Growth in Q3
- Global Sales Growth: Immuron reported third-quarter global sales of A$1.5 million, reflecting a 16% increase year-over-year, indicating the company's sustained growth potential in the market, which is likely to enhance investor confidence.
- Year-to-Date Performance: Year-to-date sales through March 2026 rose 7% to A$5.7 million, demonstrating positive outcomes from the company's overall sales strategy, which may attract more market attention.
- US Market Dynamics: In the US, Q3 sales reached A$0.5 million, up 1% from the prior comparative period, and year-to-date sales increased 10% to A$1.3 million, showcasing the company's stable performance and potential for expansion in the region.
- Investor Engagement: Immuron presented at the Emerging Growth Conference 89, drawing investor interest, which could lay the groundwork for future financing and market expansion efforts.
See More
Immuron Reports 16% Sales Growth in Q3
- Global Sales Growth: Immuron's global sales reached AUD 1.5 million in Q3 FY2026, reflecting a 16% increase compared to the prior comparative period, indicating the company's strong growth trajectory in the immune supplement market.
- Australia Market Performance: In Australia, Q3 sales amounted to AUD 0.9 million, up 15% year-on-year, driven by enhanced digital marketing efforts and an influx of new customers, further solidifying the company's leadership position in the domestic market.
- Canada Market Breakthrough: Canadian Q3 sales hit AUD 0.1 million, more than doubling year-on-year, primarily due to initial sales to Jean Coutu and effective promotional activities, showcasing a significant increase in brand awareness.
- Stable U.S. Market: U.S. Q3 sales were AUD 0.5 million, up 1% year-on-year, maintaining stability despite the challenges posed by the strengthening Australian dollar, supported by social media marketing and improvements on Amazon.
See More
Immuron CEO to Present at Coffee Microcaps Conference
- CEO Presentation Opportunity: Immuron's CEO Steven Lydeamore will present at the Coffee Microcaps Conference on March 5, 2026, showcasing the company's latest developments and strategies, which is expected to attract investor interest and enhance the company's visibility.
- Travelan® Product Introduction: Travelan®, an oral immunotherapy, effectively reduces the risk of travelers' diarrhea and is registered as a therapeutic product in Australia while being sold as a health product in Canada and the U.S., highlighting its market potential and international strategy.
- IMM-529 Development Progress: Immuron is developing IMM-529 as an adjunctive therapy for preventing and treating recurrent Clostridioides difficile infections, with preliminary clinical results showing significant efficacy in disease prevention and treatment, potentially transforming antibiotic treatment paradigms.
- ProIBS® Market Outlook: Immuron has signed an exclusive distribution agreement with Calmino Group for ProIBS®, a medical device for treating irritable bowel syndrome, which is expected to meet the demand for long-term effective treatments in the Australian and New Zealand markets, indicating substantial market potential.
See More
Immuron Reports Record Half-Year Sales of A$4.2 Million
- Sales Performance Growth: Immuron achieved record sales of A$4.2 million in the first half of FY25, reflecting a 5% increase, indicating a stable growth trend in the market despite economic uncertainties.
- Earnings Per Share Situation: The company reported an EPS of -A$0.70, highlighting ongoing challenges in achieving profitability despite sales growth, which may impact investor confidence moving forward.
- Investor Conference Participation: Immuron presented its business strategy at the Emerging Growth Conference, aiming to attract potential investors and enhance market visibility, demonstrating the company's proactive approach to future growth.
- Historical Financial Data Review: Analyzing historical financial data allows investors to better understand Immuron's performance fluctuations and future growth potential, aiding in more informed investment decisions.
See More
Immuron Reports Strong H1 FY26 Financial Results and Strategic Developments
- Consistent Revenue Growth: Immuron's H1 FY26 sales reached AUD 4.2 million, reflecting a 17% year-over-year increase, particularly driven by strong momentum in the U.S. market, indicating enhanced competitiveness on a global scale.
- Strong Cash Position: The company holds AUD 10 million in cash to fund operations, including AUD 7.3 million raised at an average price of AUD 0.0803 per share, providing a solid financial foundation for future R&D and market expansion.
- Validated Platform with New Targets: Immuron's 'Hyper-Immune' platform has proven successful in treating traveler's diarrhea (Travelan®) and is now targeting high-value clinical applications like C. difficile (IMM-529), showcasing the versatility and market potential of its technology.
- Strategic Partnerships: The company has opted to pursue partnerships to advance the clinical programs for Travelan® (IMM-124E) and IMM-529, with IMM-124E qualifying for an end-of-Phase 2 meeting with the FDA, indicating significant progress in its clinical development.
See More
Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy
- Strategic Partnership: Immuron has engaged Pullan Consulting to leverage their expertise in biotechnology to advance the clinical development and commercialization of IMM-529, thereby enhancing the product's market value and accelerating its path to market.
- FDA Approval Progress: The clinical development of IMM-529 has received IND approval from the U.S. FDA specifically for the prevention and treatment of Clostridioides difficile infection (CDI), establishing a solid foundation for market entry and potentially addressing a market need affecting over 400,000 individuals annually.
- Clinical Trial Design: The Phase 2 clinical trial for IMM-529 will enroll up to 60 patients using a randomized, double-blind, placebo-controlled design, primarily assessing safety and tolerability, which aligns with the fast-track Clinical Trial Notification (CTN) scheme and will provide critical data for future market promotion.
- Market Potential Assessment: According to Lumanity's assessment, if IMM-529 proves effective, it could generate annual revenues of $400 million, and its early positioning in treatment algorithms will provide a competitive advantage in a crowded market, further driving Immuron's business growth.
See More
Immuron Reports 16% Sales Growth in Q3
- Global Sales Growth: Immuron reported third-quarter global sales of A$1.5 million, reflecting a 16% increase year-over-year, indicating the company's sustained growth potential in the market, which is likely to enhance investor confidence.
- Year-to-Date Performance: Year-to-date sales through March 2026 rose 7% to A$5.7 million, demonstrating positive outcomes from the company's overall sales strategy, which may attract more market attention.
- US Market Dynamics: In the US, Q3 sales reached A$0.5 million, up 1% from the prior comparative period, and year-to-date sales increased 10% to A$1.3 million, showcasing the company's stable performance and potential for expansion in the region.
- Investor Engagement: Immuron presented at the Emerging Growth Conference 89, drawing investor interest, which could lay the groundwork for future financing and market expansion efforts.
See More
Immuron Reports 16% Sales Growth in Q3
- Global Sales Growth: Immuron's global sales reached AUD 1.5 million in Q3 FY2026, reflecting a 16% increase compared to the prior comparative period, indicating the company's strong growth trajectory in the immune supplement market.
- Australia Market Performance: In Australia, Q3 sales amounted to AUD 0.9 million, up 15% year-on-year, driven by enhanced digital marketing efforts and an influx of new customers, further solidifying the company's leadership position in the domestic market.
- Canada Market Breakthrough: Canadian Q3 sales hit AUD 0.1 million, more than doubling year-on-year, primarily due to initial sales to Jean Coutu and effective promotional activities, showcasing a significant increase in brand awareness.
- Stable U.S. Market: U.S. Q3 sales were AUD 0.5 million, up 1% year-on-year, maintaining stability despite the challenges posed by the strengthening Australian dollar, supported by social media marketing and improvements on Amazon.
See More
Immuron CEO to Present at Coffee Microcaps Conference
- CEO Presentation Opportunity: Immuron's CEO Steven Lydeamore will present at the Coffee Microcaps Conference on March 5, 2026, showcasing the company's latest developments and strategies, which is expected to attract investor interest and enhance the company's visibility.
- Travelan® Product Introduction: Travelan®, an oral immunotherapy, effectively reduces the risk of travelers' diarrhea and is registered as a therapeutic product in Australia while being sold as a health product in Canada and the U.S., highlighting its market potential and international strategy.
- IMM-529 Development Progress: Immuron is developing IMM-529 as an adjunctive therapy for preventing and treating recurrent Clostridioides difficile infections, with preliminary clinical results showing significant efficacy in disease prevention and treatment, potentially transforming antibiotic treatment paradigms.
- ProIBS® Market Outlook: Immuron has signed an exclusive distribution agreement with Calmino Group for ProIBS®, a medical device for treating irritable bowel syndrome, which is expected to meet the demand for long-term effective treatments in the Australian and New Zealand markets, indicating substantial market potential.
See More
Immuron Reports Record Half-Year Sales of A$4.2 Million
- Sales Performance Growth: Immuron achieved record sales of A$4.2 million in the first half of FY25, reflecting a 5% increase, indicating a stable growth trend in the market despite economic uncertainties.
- Earnings Per Share Situation: The company reported an EPS of -A$0.70, highlighting ongoing challenges in achieving profitability despite sales growth, which may impact investor confidence moving forward.
- Investor Conference Participation: Immuron presented its business strategy at the Emerging Growth Conference, aiming to attract potential investors and enhance market visibility, demonstrating the company's proactive approach to future growth.
- Historical Financial Data Review: Analyzing historical financial data allows investors to better understand Immuron's performance fluctuations and future growth potential, aiding in more informed investment decisions.
See More
Immuron Reports Strong H1 FY26 Financial Results and Strategic Developments
- Consistent Revenue Growth: Immuron's H1 FY26 sales reached AUD 4.2 million, reflecting a 17% year-over-year increase, particularly driven by strong momentum in the U.S. market, indicating enhanced competitiveness on a global scale.
- Strong Cash Position: The company holds AUD 10 million in cash to fund operations, including AUD 7.3 million raised at an average price of AUD 0.0803 per share, providing a solid financial foundation for future R&D and market expansion.
- Validated Platform with New Targets: Immuron's 'Hyper-Immune' platform has proven successful in treating traveler's diarrhea (Travelan®) and is now targeting high-value clinical applications like C. difficile (IMM-529), showcasing the versatility and market potential of its technology.
- Strategic Partnerships: The company has opted to pursue partnerships to advance the clinical programs for Travelan® (IMM-124E) and IMM-529, with IMM-124E qualifying for an end-of-Phase 2 meeting with the FDA, indicating significant progress in its clinical development.
See More
